The PMP22 Gene CMT1A Genetic Test is a specialized diagnostic procedure designed to identify mutations in the PMP22 gene, which are closely associated with Charcot-Marie-Tooth disease type 1A (CMT1A). CMT1A is a hereditary neurological disorder that affects the peripheral nerves, leading to muscle weakness and sensory problems primarily in the arms and legs. The test is crucial for confirming a diagnosis, understanding the risk of passing the condition to offspring, and guiding treatment decisions.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, this test offers a reliable analysis of the PMP22 gene. DNA Labs UAE utilizes advanced genetic sequencing technologies to detect the presence of the duplication or other mutations in the PMP22 gene that are indicative of CMT1A. This precise approach ensures high accuracy in diagnosis, which is essential for effective management and counseling of affected individuals and their families.
The cost of the PMP22 Gene CMT1A Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis and the professional interpretation of results by experienced genetic counselors. Given the specialized nature of this test and the profound impact it can have on patients' lives, it represents a significant step towards personalized medicine in the realm of neurological disorders.
The LITAF gene CMT1C genetic test is a specialized diagnostic examination designed to detect mutations in the LITAF gene, which are associated with Charcot-Marie-Tooth disease type 1C (CMT1C). Charcot-Marie-Tooth disease is a group of inherited disorders that affect the peripheral nerves, leading to muscle weakness and atrophy, particularly in the extremities. CMT1C specifically involves a mutation in the LITAF gene, which plays a crucial role in the development and function of peripheral nerves.
This test is particularly important for individuals who have a family history of Charcot-Marie-Tooth disease or exhibit symptoms consistent with peripheral neuropathy, such as muscle weakness, decreased muscle size, reduced sensation, and difficulty with balance. Early diagnosis through genetic testing can aid in the management of the condition, including physical therapy, occupational therapy, and possibly surgical interventions to improve quality of life.
The LITAF gene CMT1C genetic test is available at DNA Labs UAE, a leading facility in genetic diagnostics and personalized medicine. The cost of the test is 4400 AED. DNA Labs UAE employs cutting-edge technology and adheres to strict quality control measures to ensure accurate and reliable results. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the LITAF gene.
By opting for this test at DNA Labs UAE, individuals can gain valuable insights into their genetic makeup, empowering them with information that can help in the management of Charcot-Marie-Tooth disease and enhancing their overall well-being.
The EGR2 Gene CMT1D Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the EGR2 gene, which are associated with Charcot-Marie-Tooth disease type 1D (CMT1D). CMT1D is a type of inherited neurological disorder that affects the peripheral nerves, leading to muscle weakness and sensory problems primarily in the arms and legs. The test plays a crucial role in the early detection and management of the condition, allowing for personalized treatment plans and genetic counseling for affected individuals and their families. Conducted in the state-of-the-art facilities of DNA Labs UAE, the test is priced at 4400 AED, reflecting the intricate technology and expertise involved in detecting the specific genetic alterations linked to CMT1D.
The PMP22 Gene CMT1E Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the PMP22 gene, which are associated with Charcot-Marie-Tooth disease type 1E (CMT1E). This condition is a form of hereditary neuropathy that affects the peripheral nerves, leading to muscle weakness and sensory problems. The test is particularly crucial for individuals displaying symptoms of CMT1E or those with a family history of the disease, as it can provide definitive genetic evidence of the condition.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed for specific mutations in the PMP22 gene. The results from this test can help in making an accurate diagnosis, guiding treatment decisions, and offering genetic counseling for affected individuals and their families.
The cost of the PMP22 Gene CMT1E Genetic Test at DNA Labs UAE is set at 4400 AED. This price includes the full process of sample collection, genetic analysis, and the provision of a comprehensive report detailing the findings. Individuals considering this test are encouraged to consult with a healthcare provider or a genetic counselor to understand the implications of the results and the next steps in the management of the condition.
The KIF1B gene plays a crucial role in the development and function of peripheral nerves. Mutations in the KIF1B gene are associated with Charcot-Marie-Tooth disease type 2A1 (CMT2A1), a genetic disorder characterized by the degeneration of peripheral nerves, leading to muscle weakness and sensory loss primarily in the arms and legs. The CMT2A1 genetic test is a specialized diagnostic tool designed to detect mutations in the KIF1B gene, confirming the diagnosis of CMT2A1 and facilitating appropriate clinical management and genetic counseling.
Performed at DNA Labs UAE, the CMT2A1 genetic test is conducted using advanced genetic sequencing technologies to provide accurate and reliable results. The test is priced at 4400 AED and is aimed at individuals who have clinical symptoms of CMT2A1 or have a family history of the disease. Early and precise diagnosis through the CMT2A1 genetic test can be crucial for the management of symptoms, understanding the risk of transmission to offspring, and exploring potential treatment options.
The MFN2 gene is associated with Charcot-Marie-Tooth disease type 2A2 (CMT2A2), a condition characterized by the degeneration of peripheral nerves that primarily affects the muscles and sensory systems of the body. The MFN2 gene plays a crucial role in the maintenance and function of these nerves. Mutations in the MFN2 gene disrupt these processes, leading to the symptoms observed in individuals with CMT2A2, including muscle weakness, decreased muscle size, sensory loss, and in some cases, foot deformities.
The MFN2 Gene CMT2A2 Genetic Test is a specialized diagnostic tool used to identify mutations in the MFN2 gene that are responsible for CMT2A2. This test is essential for confirming the diagnosis, understanding the prognosis, and guiding the management and treatment strategies for individuals suspected of having CMT2A2. Additionally, the test can be valuable for family planning decisions for those with a history of the condition.
Conducted at DNA Labs UAE, a leading facility in genetic testing, the test ensures high accuracy and reliability. The cost of the MFN2 Gene CMT2A2 Genetic Test is 4400 AED. This price reflects the comprehensive nature of the test, covering the analysis, interpretation, and reporting conducted by experienced geneticists. The test results can provide crucial insights into the genetic basis of the condition, enabling personalized care and management plans for affected individuals and their families.
The ATP1A3 gene CAPOS syndrome genetic test is a specialized diagnostic procedure aimed at identifying mutations in the ATP1A3 gene, which are linked to CAPOS syndrome. CAPOS syndrome is a rare genetic disorder characterized by Cerebellar Ataxia, Areflexia, Pes cavus, Optic atrophy, and Sensorineural hearing loss. This condition is inherited in an autosomal dominant pattern, meaning a mutation in just one of the two copies of the gene can lead to the disorder.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in a laboratory to detect the presence of genetic mutations associated with the syndrome. This genetic testing is crucial for accurate diagnosis, guiding treatment options, and providing information on the risk of passing the condition to future generations.
Conducted at DNA Labs UAE, the test is priced at 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology and staffed by experienced professionals to ensure accurate and reliable results. The facility provides a supportive environment for patients and their families, offering comprehensive counseling and support services alongside genetic testing.
The RYR1 Gene Central Core Disease Genetic Test is a specialized diagnostic procedure designed to identify mutations in the RYR1 gene, which are associated with Central Core Disease (CCD). CCD is a rare genetic condition characterized by muscle weakness, skeletal abnormalities, and an increased risk of malignant hyperthermia, a severe reaction to certain anesthesia drugs. This test involves analyzing the patient's DNA to detect any abnormalities in the RYR1 gene that could indicate the presence of CCD.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability in results, thanks to their state-of-the-art technology and expert team. The cost of the test is set at 4400 AED, reflecting the comprehensive analysis and detailed reporting provided. By identifying the genetic basis of CCD, this test enables targeted management strategies, personalized care, and informed family planning decisions for affected individuals and their families.
The ASCL1 gene plays a critical role in the development and function of the autonomic nervous system, which controls involuntary actions such as breathing. Mutations in the ASCL1 gene can lead to Congenital Central Hypoventilation Syndrome (CCHS), a rare genetic disorder characterized by the failure to automatically control breathing. This means affected individuals do not adequately ventilate, especially during sleep, leading to a risk of hypoventilation (underbreathing), which can result in life-threatening complications.
To diagnose this condition, genetic testing of the ASCL1 gene can be conducted. DNA Labs UAE offers a comprehensive genetic test specifically designed to identify mutations in the ASCL1 gene that are associated with Congenital Central Hypoventilation Syndrome. This test is crucial for the accurate diagnosis and management of the condition, allowing for appropriate treatment and monitoring strategies to be implemented, enhancing the quality of life for affected individuals.
The cost of the ASCL1 Gene Central Hypoventilation Syndrome Congenital Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the genetic analysis and professional interpretation of the results, ensuring that patients and their families receive accurate and actionable information. This test is an essential tool in the management of CCHS, providing a clear genetic diagnosis that can guide treatment decisions and support family planning considerations.
The DNM2 Gene Centronuclear Myopathy Type 1 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the DNM2 gene, which are responsible for Centronuclear Myopathy Type 1. This condition is a rare genetic disorder characterized by muscle weakness and abnormalities in the placement of nuclei in muscle cells. The test is crucial for early diagnosis, enabling timely intervention and management of the condition. Priced at 4400 AED, the test involves analyzing the patient's DNA to identify specific genetic alterations in the DNM2 gene, providing insights into the risk and guiding treatment options for affected individuals and their families.
